In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70)
Autor: | Katarzyna Kabelis, Paul W. Sanders, Bernard Rees Smith, Jane Wilmot, Michele Evans, Jadwiga Furmaniak, Jane Sanders, Stuart Young, Jill Clark |
---|---|
Rok vydání: | 2011 |
Předmět: |
endocrine system
medicine.medical_specialty endocrine system diseases Graves' disease Immunology Autoimmunity Follicular cell Rheumatology In vivo Internal medicine medicine Thyroid-blocking antibodies TSH receptor Receptor Thyroid business.industry Autoantibody medicine.disease Thyroid-stimulating antibodies Endocrinology medicine.anatomical_structure Monoclonal Original Article Graves’ disease business Hormone |
Zdroj: | Auto-Immunity Highlights |
ISSN: | 2038-3274 2038-0305 |
DOI: | 10.1007/s13317-011-0025-9 |
Popis: | Purpose To study in vivo effects of the human monoclonal TSH receptor (TSHR) autoantibodies M22 (stimulating type) and K1-70 (blocking type) on thyroid hormone levels in rats. Methods Serum levels of total T4, free T4, M22 and K1-70 were measured following intramuscular injection of M22 IgG (2–4 μg/animal), K1-70 IgG (10–200 μg/animal) or both into rats. Thyroid pathology was assessed in M22-injected rats. Results Serum levels of total T4 and free T4 increased in a dose-dependent manner following injection of M22 IgG. Thyroid follicular cell hypertrophy was dependent on the dose of M22 IgG. K1-70 IgG caused a dose dependent decrease of total T4 and free T4 levels in rats receiving K1-70 only. The stimulating effects of M22 IgG on T4 levels in rats were completely inhibited by K1-70 IgG. Conclusion M22 is a potent stimulator of thyroid hormone secretion in vivo. In contrast, K1-70 inhibits thyroid hormone secretion in vivo. Furthermore, K1-70 has the ability to inhibit the stimulating activity of M22 in vivo and as such has potential as a new drug to block TSHR stimulation by autoantibodies in Graves’ disease. |
Databáze: | OpenAIRE |
Externí odkaz: |